| Oxford Nanopore Technologies plc | |
|---|---|
| Type | Public limited company |
| ISIN | GB00BP6S8Z30 |
| Industry | Nanopore sequencing |
| Founded | 2005 |
| Founders |
|
| Headquarters | , |
| Key people |
|
| Revenue | |
| Website | nanoporetech |
Oxford Nanopore Technologies plc is a UK-based company which develops and sells nanopore-based molecular sensing technology for the real-time analysis of DNA and RNA. Its platform includes sequencing devices, consumables and software used across research, applied and clinical markets. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
The company was founded in 2005 as a spin-out from the University of Oxford by Hagan Bayley, Gordon Sanghera, and Spike Willcocks, with seed funding from the IP Group. The company made an initial public offering on the London Stock Exchange on 30 September 2021, under the ticker ONT.
In March 2016 the company announced a chemistry upgrade to its nanopore sequencing product 'R9', using a protein nanopore in collaboration with the laboratory of Han Remaut (VIB/Vrije Universiteit Brussel). The company stated in a webcast that R9 is designed to improve error rates and yield.

In December 2025, the company announced that Francis Van Parys would succeed Gordon Sanghera as CEO. Prior to joining Oxford Nanopore, he was President and CEO of Radiometer and held senior leadership roles at Cytiva and GE Healthcare.

The main products of Oxford Nanopore are:
These products are intended to be used for the analysis of DNA, RNA, proteins and small molecules with a range of applications in personalized medicine, Agricultural science and scientific research.
{{citation}}: CS1 maint: work parameter with ISBN (link){{cite web}}: CS1 maint: url-status (link)